Get the Stockscreener App
3.20
1.84%
-0.06
After Hours:
3.20
Cardlytics Inc stock is traded at $3.20, with a volume of 533.03K.
It is down -1.84% in the last 24 hours and down -18.16% over the past month.
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K., and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.
See More
Previous Close:
$3.26
Open:
$3.24
24h Volume:
533.03K
Relative Volume:
0.46
Market Cap:
$159.49M
Revenue:
$312.80M
Net Income/Loss:
$-115.27M
P/E Ratio:
-0.2938
EPS:
-10.89
Net Cash Flow:
$-12.58M
1W Performance:
-5.60%
1M Performance:
-18.16%
6M Performance:
-77.92%
1Y Performance:
-80.61%
1-Day Range:
$3.16
$3.41
1-Week Range:
$3.16
$3.4699
52-Week Range:
$2.8901
$20.52
Cardlytics Inc Stock (CDLX) Company Profile
Name
Cardlytics Inc
Sector
Industry
Phone
888-798-5802
Address
675 PONCE DE LEON AVENUE, NE, ATLANTA, GA
Cardlytics Inc Stock (CDLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-13-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-12-22 | Downgrade | Craig Hallum | Buy → Hold |
| Apr-05-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | Needham | Buy |
| Apr-15-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-14-21 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-05-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-04-20 | Downgrade | Craig Hallum | Buy → Hold |
| Jan-15-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-02-19 | Initiated | Craig Hallum | Buy |
| Nov-14-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Jul-01-19 | Initiated | William Blair | Outperform |
| Jan-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
View All
Cardlytics Inc Stock (CDLX) Latest News
Is Cardlytics, Inc. (CDLX) the Worst Advertising Stock to Buy According to Short Sellers? - Insider Monkey
Is Cardlytics, Inc. (CDLX) the Worst Advertising Stock to Buy According to Short Sellers? - Yahoo Finance
CDLX Shares Experience Decline in Value - Knox Daily
Is Cardlytics, Inc. (CDLX) the Worst Marketing Stock to Buy? - Insider Monkey
Is Cardlytics, Inc. (CDLX) the Worst Marketing Stock to Buy? - Yahoo Finance
Cardlytics, Inc. (NASDAQ:CDLX) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
Cardlytics (CDLX) Under Investor Scrutiny About Growth Initiatives – Hagens Berman - GlobeNewswire
Cardlytics, Inc. (CDLX): A Bull Case Theory - Insider Monkey
Cardlytics, Inc. (CDLX): A Bull Case Theory - Yahoo Finance
10 Worst Marketing Stocks to Buy - Insider Monkey
Understanding the Risks of Investing in Cardlytics Inc (CDLX) - Knox Daily
Stifel’s latest rating for CLDX stock - Knox Daily
Closing Figures Unveiled: Cardlytics Inc (CDLX) Drop -5.41, Closes at 3.67 - The Dwinnex
Cosciens Biopharma Shares Fall on ALS Treatment Research End, Cost Cutting - MarketWatch
DRW Securities LLC Acquires New Holdings in Calumet Specialty Products Partners, L.P. (NASDAQ:CLMT) - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) is Yu Fan's 4th Largest Position - MarketBeat
Comparing BioLargo (NASDAQ:BLGO) and Chemours (NYSE:CC) - Defense World
Blair William & Co. IL Has $9.71 Million Position in Carrier Global Co. (NYSE:CARR) - Defense World
Bank of New York Mellon Corp Grows Holdings in Cardlytics, Inc. (NASDAQ:CDLX) - Defense World
StockNews.com Begins Coverage on Calumet Specialty Products Partners (NASDAQ:CLMT) - Defense World
Bragar Eagel & Squire, P.C. Is Investigating LPL Financial, Bumble, Cardlytics, and European Wax and Encourages Investors to Contact the Firm - ForexTV.com
Bragar Eagel & Squire, P.C. Is Investigating LPL Financial, Bumble, Cardlytics, and European Wax and Encourages Investors to Contact the Firm - Morningstar
Bragar Eagel & Squire, P.C. Is Investigating LPL Financial, - GlobeNewswire
10 Worst Advertising Stocks To Buy According to Short Sellers - Insider Monkey
Favourable Signals For Cardlytics: Numerous Insiders Acquired Stock - Yahoo Finance
Cardlytics Inc [NASDAQ: CDLX] Sees Increase in Stock Value - Knox Daily
Pekin Hardy Strauss Inc. Acquires New Shares in Cardlytics, Inc. (NASDAQ:CDLX) - Defense World
CAH Stock May Gain Following the Distribution Agreement With Telix - Yahoo Finance
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cardlytics, Inc.CDLX - PR Newswire
Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating) - Seeking Alpha
Can you now get a good deal on Celldex Therapeutics Inc.’s shares? - US Post News
Cardlytics Inc (CDLX)’s stock price in review: A technical analysis - US Post News
Quest Partners LLC Grows Position in Cardlytics, Inc. (NASDAQ:CDLX) - Defense World
Cardlytics (CDLX) Under Investor Scrutiny About Growth Initiatives – Hagens Berman - GlobeNewswire Inc.
Institutional owners may consider drastic measures as Cardlytics, Inc.'s (NASDAQ:CDLX) recent US$24m drop adds to long-term losses - Simply Wall St
Cardlytics (NASDAQ:CDLX) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga
Cardlytics Inc Is Being Looked Into For Violating Securities Regulations And Stakeholders Are Urged To Spearhead The Investigation - StockTitan
CDLX Investors Have Opportunity to Join Cardlytics, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire
Bragar Eagel & Squire, P.C. Is Investigating Paragon 28, - GlobeNewswire
Cardlytics, Inc. (NASDAQ:CDLX) Receives $7.50 Consensus Target Price from Analysts - MarketBeat
Cardlytics, Inc. (NASDAQ:CDLX) Given Consensus Rating of “Reduce” by Analysts - Defense World
Cardlytics, Inc. (NASDAQ:CDLX) Short Interest Update - MarketBeat
Cardlytics, Inc. (NASDAQ:CDLX) Short Interest Update - Defense World
CDLX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Cardlytics, Inc. and Encourages Clients to Contact the Firm! - AccessWire
You might want to take a look at Cardlytics Inc (CDLX) now - SETE News
Baillie Gifford & Co. Has $6.81 Million Holdings in Cardlytics, Inc. (NASDAQ:CDLX) - Defense World
Cardlytics, Inc. (CDLX) Investigation: Bronstein, Gewirtz & - GlobeNewswire
A year in review: Cardlytics Inc (CDLX)’s performance in the last year - US Post News
Quarterly Metrics: Quick and Current Ratios for Cardlytics Inc (CDLX) - The Dwinnex
Bragar Eagel & Squire, P.C. Is Investigating Arhaus, Cardlytics, and CVRx and Encourages Investors to Contact the Firm - ForexTV.com
Bragar Eagel & Squire, P.C. Is Investigating Arhaus, Cardlytics, and CVRx and Encourages Investors to Contact the Firm - GlobeNewswire
Cardlytics Inc Stock (CDLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
2.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):